AI Article Synopsis

  • Studies show differences in characteristics and outcomes for metastatic colorectal cancer (mCRC) patients based on whether they were treated in public or private hospitals in South Australia.
  • A comprehensive study analyzed data from 3,470 mCRC patients, revealing that public hospital patients tend to have a higher burden of disease and receive less treatment compared to those in private hospitals.
  • Results indicated that after adjustments, public patients had a shorter survival time by 1.33 months than private patients, highlighting disparities in care and outcomes.

Article Abstract

Background: Studies have reported significant differences in baseline characteristics and outcomes of metastatic colorectal cancer (mCRC) patients when managed in private versus public hospitals.

Aims: To compare disease, treatment and survival outcomes of patients with mCRC in public versus private hospitals in South Australia (SA).

Methods: Analysis of prospectively collected data from the SA mCRC Registry. Patterns of care and outcome data according to location of care and socioeconomic status based on Index of Relative Socio-Economic Advantage and Disadvantage were analysed.

Results: A total of 3470 patients' data was analysed during February 2006-January 2015. The majority (70%) of patients received treatment in public hospitals. Patients in the upper 50% for Index of Relative Socio-Economic Advantage and Disadvantage score were more likely to receive treatment at a private hospital (41.2% vs 21.56%) compared to <50%. Public patients had higher burden of disease (10.49% vs 7.41%, P = 0.005). Public patients received less treatment compared to the private patients (odds ratio = 0.48 (0.38-0.61), P = 0.01) and rates of surgical resections were lower in public patients. After adjusting for the covariates, public patients survive 1.33 months (P = 0.025) shorter than private patients with follow-up time of 5 years. Patients receiving metastasectomy and more than three lines of treatment were shown to have the greatest survival benefit.

Conclusion: Public patients have a higher burden of disease and in comparison are less likely to receive systemic therapy and have lower survival than patients treated in private hospitals.

Download full-text PDF

Source
http://dx.doi.org/10.1111/imj.14765DOI Listing

Publication Analysis

Top Keywords

metastatic colorectal
12
colorectal cancer
12
outcomes metastatic
8
private hospitals
8
hospitals south
8
relative socio-economic
8
socio-economic advantage
8
advantage disadvantage
8
patients
5
treatment
4

Similar Publications

Advancements in immunotherapy for colorectal cancer treatment: a comprehensive review of strategies, challenges, and future prospective.

Int J Colorectal Dis

December 2024

Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Kelambakkam, Chennai, Tamil Nadu, 603103, India.

Purpose: Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide. Metastatic colorectal cancer (mCRC) continues to present significant challenges, particularly in patients with proficient mismatch repair/microsatellite stable (pMMR/MSS) tumors. This narrative review aims to provide recent developments in immunotherapy for CRC treatment, focusing on its efficacy and challenges.

View Article and Find Full Text PDF

Improving colonoscopy quality in the national VA healthcare system.

Contemp Clin Trials

December 2024

San Francisco VA Medical Center, United States of America; Department of Medicine, University of California, San Francisco, CA, United States of America; Measurement Science Quality Enhancement Research Initiative, San Francisco VA Healthcare System, United States of America. Electronic address:

Background: Colorectal cancer (CRC) prevention is a Veterans Affairs (VA) priority. Colonoscopy quality, especially adenoma detection rate (ADR), is critical for effective screening. Our research indicates considerable variation in ADR among VA providers.

View Article and Find Full Text PDF

Individual FiO guided by SO prevents hyperoxia and reduces postoperative atelectasis in colorectal surgery: A randomized controlled trial.

J Clin Anesth

December 2024

Department of Anesthesiology, Second Affiliated Hospital of Harbin Medical University, China; The Key Laboratory of Anesthesiology and Intensive Care Research of Heilongjiang Province, China. Electronic address:

Study Objective: To determine whether individualized fraction of inspired oxygen (iFiO) improves pulmonary atelectasis after elective laparoscopic colorectal surgery relative to 60 % FiO.

Design: This was a single-center, prospective, randomized study.

Setting: This study was conducted in a single tertiary care hospital in China.

View Article and Find Full Text PDF

Metastasis in patients with oral squamous cell carcinoma has been associated with a poor prognosis. However, sensitive and reliable tests for monitoring their occurrence are unavailable, with the exception of PET-CT. Circulating tumor cells and cell-free DNA have emerged as promising biomarkers for determining treatment efficacy and as prognostic predictors in solid tumors such as breast cancer and colorectal cancer.

View Article and Find Full Text PDF

Epidermal growth factor receptor (EGFR) inhibition is crucial in treating RAS wild-type metastatic colorectal cancer, yet current testing methods may miss rare RAS variants affecting treatment efficacy. We analyzed 4122 colorectal cancer patients receiving anti-EGFR antibodies from the Center for Cancer Genomics and Advanced Therapeutics database, identifying 54 patients (1.3%) with rare RAS variants undetectable by standard testing.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!